Aprea Therapeutics, Inc. (APRE) Stock
Healthcare · Biotechnology · US
$0.95
+29.89%
Last updated Jun 18, 2026 23:53 UTC
APRE Key Statistics
Market Cap$6.19M
P/E (TTM)-0.48
P/S (TTM)21.67
P/B (TTM)0.59
Revenue (TTM)$285,759.00
EPS (TTM)$-1.98
Dividend Yield—
ROE (TTM)-93.72%
Net Margin-4,409.16%
Gross Margin92.40%
52W High$0.96
52W Low$0.60
Analyst ViewBuy
Price Target—
Employees8
Volume563,992
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
CEO: Oren Gilad. Company website
See APRE live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open APRE in Terminal See plans